Advertisement
Advertisement
KNSA
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
53.50
USDSponsored
-0.28
-0.51%
May 01, 12:18 UTC -4
Open
KNSA Earnings Reports
Positive Surprise Ratio
KNSA beat 19 of 32 last estimates.
59%
Next Report
Date of Next Report
Jul 27, 2026
Estimate for Q2 26 (Revenue/ EPS)
$226.68M
/$0.26
Implied change from Q1 26 (Revenue/ EPS)
+5.79%
/-3.70%
Implied change from Q2 25 (Revenue/ EPS)
+44.57%
/+13.04%
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares earnings per share and revenue
On Apr 28, 2026, KNSA reported earnings of 0.27 USD per share (EPS) for Q1 26, beating the estimate of 0.20 USD, resulting in a 31.51% surprise. Revenue reached 214.27 million, compared to an expected 210.21 million, with a 1.93% difference. The market reacted with a +23.48% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 0.26 USD, with revenue projected to reach 226.68 million USD, implying an decrease of -3.70% EPS, and increase of 5.79% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bio-Rad Laboratories, Inc. Class B
Report Date
Apr 30, 2026 For Q1 26
Estimate
$2.00
Actual
$1.89
Surprise
-5.68%
Kymera Therapeutics, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.89
Actual
-$0.71
Surprise
+21.05%
Syndax Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.59
Actual
-$0.48
Surprise
+19.15%
Amgen Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$4.85
Actual
$5.15
Surprise
+6.15%
Bristol-Myers Squibb Co.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.42
Actual
$1.58
Surprise
+10.95%
Alnylam Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.95
Actual
$1.99
Surprise
+108.95%
Moderna, Inc. Common Stock
Report Date
May 01, 2026 For Q1 26
Estimate
-$3.32
Actual
-$1.18
Surprise
+64.48%
Illumina Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.07
Actual
$1.14
Surprise
+6.94%
NovoCure Limited Ordinary Shares
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.52
Actual
-$0.62
Surprise
-18.52%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.32
Actual
-$0.18
Surprise
+45.22%
FAQ
What were Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares reported EPS of $0.27, beating estimates by 31.51%, and revenue of $214.27M, 1.93% above expectations.
How did the market react to Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Q1 2026 earnings?
The stock price moved up 23.48%, changed from $43.61 before the earnings release to $53.85 the day after.
When is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares expected to report next?
The next earning report is scheduled for Jul 27, 2026.
What are the forecasts for Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's next earnings report?
Based on 6
analysts, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares is expected to report EPS of $0.26 and revenue of $226.68M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement